Journal
JOURNAL OF DIABETES RESEARCH
Volume 2019, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.1155/2019/7602427
Keywords
-
Funding
- Science and Technology Innovation Joint Fund Project Fujian Province [2016Y9102]
- National Natural Science Foundation of China [81500632, 81870572]
- Natural Science Foundation of Fujian Province [2019J01455, 2015J01453]
- Fujian Province Higher Education Institute New Century Research Project [2018B049]
- Medical Innovation Fund Project of Fujian Province [2018-CX-23]
Ask authors/readers for more resources
Background and Purpose. Metformin, a widely used antidiabetic drug, has been shown to have anti-inflammatory properties; nevertheless, its influence on beta-cell meta-inflammation remains unclear. The following study investigated the effects of metformin on meta-inflammatory in beta-cells and whether the underlying mechanisms were associated with the G protein-coupled receptor 40-phospholipase C-inositol 1, 4, 5-trisphosphate (GPR40-PLC-IP3) pathway. Materials and Methods. Lipotoxicity-induced beta-cells and the high-fat diet-induced obese rat model were used in the study. Results. Metformin-reduced lipotoxicity-induced beta-cell meta-inflammatory injury was associated with the expression of GPR40. GPR40 was involved in metformin reversing metabolic inflammation key marker TLR4 activation-mediated beta-cell injury. Furthermore, downstream signaling protein PLC-IP3 of GPR40 was involved in the protective effect of metformin on meta-inflammation, and the above process of metformin was partially regulated by AMPK activity. In addition, the anti-inflammatory effects of metformin were observed in obese rats. Conclusion. Metformin can reduce lipotoxicity-induced meta-inflammation in beta-cells through the regulation of the GPR40-PLC-IP3 pathway and partially via the regulation of AMPK activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available